Use of transgenic animals in xenotransplantation

Transplantation Reviews

Volumn 10, Issue 2, 1996, Pages 69-77

  Platt, Jeffrey L ^a   Logan, John S ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002498594     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(96)80013-9     Document Type: Article

References (52)

1. Hoke F: As cross-species transplantation forges ahead, some researchers call for caution. The Scientist 1995, 9:1
2. Platt JL, Fischel RJ, Matas AJ, et al: Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991, 52:214
3. Platt, JL: Hyperacute xenograft rejection. Austin, TX, R.G. Landes Company, 1995
4. Gewurz H, Clark DS: Participation of complement and complement-fixing antibody in the rejection of vascularized grafts. J Lab Clin Med 1964, 64:861
5. Gewurz H, Clark DS, Finstad J, et al: Role of the complement system in graft rejections in experimental animals and man. Ann NY Acad Sci 1966, 129:673
6. Chartrand C, O'Regan S, Robitaille P, et al: Delayed rejection of cardiac xenografts in C6-deficient rabbits. J Immunol 1979, 38:245
7. Zhow XJ, Niesen N, Pawlowski I, et al: Prolongation of survival of discordant kidney xenografts by C6 deficiency. Transplantation 1990, 50:896
8. Brauer RB, Baldwin III WM, Daha MR, et al: Use of Co-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993, 151:7240
9. Gewurz H, Clark DS, Cooper MD, et al: Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967, 5:1296
10. Leventhal JR, Dalmasso AP, Cromwell JW, et al: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993, 55:857
11. Pruitt SK, Baldwin III WM, Marsh Jr HC, et al: The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991, 52:868
12. Pruitt SK, Kirk AD, Bollinger RR, et al: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994, 57:363
13. Vercellotti GM, Platt JL, Bach FH, et al: Enhanced neutrophil adhesion to xenogeneic endothelium via C3bi. J Immunol 1991, 146:730
14. Goldstein IM: Complement: Biologically active products, in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation: Basic principles and clinical correlates, New York, NY: Raven, 1992, pp 63-80
15. Shin ML, Carney DF: Cytotoxic action and other metabolic consequences of terminal complement proteins. Prog in Allergy 1988, 40:44
16. Morgan BP: Complement membrane attack on nucleated cells: Resistance, recovery, and non-lethal effects. Biochem J 1989, 264:1
17. Saadi S, Holzkhecht RA, Patte CP, et al: Complement-mediated regulation of the tissue factor activity in endothelium. J Exp Med 1995, 182:1807
18. Horstmann RD, Pangburn MK, Müller-Eberhard HJ: Species specificity of recognition by the alternative pathway of complement. J Immunol 1985, 134:1101
19. Hansch GM, Hammer CH, Vanguri P, et al: Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 1981, 78:5118
20. Pangburn MK, Schreiber RD, Muller-Eberhard HJ: Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983, 80:5430
21. Nicholson-Weller A, March JP, Rosenfeld SI, et al: Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983, 80:5066
22. Matsuo S, Ichida S, Takizawa H, et al: In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med 1994, 180:1619
23. Miyagawa S, Hirose H, Shirakura R, et al: The mechanism of discordant xenograft rejection. Transplantation 1988, 46:825
24. Dalmasso AP, Vercellotti GM, Platt JL, et al: Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: Potential for prevention of xenograft hyperacute rejection. Transplantation 1991, 52:530
25. Platt JL, Vercellotti GM, Dalmasso AP, et al: Transplantation of discordant xenografts: A review of progress. Immunol Today 1990, 11:450
26. Walsh LA, Tone M, Waldmann H: Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur J Immunol 1991, 21:847
27. Platt JL, Bach FH: The barrier to xenotransplantation. Transplantation 1991, 52:937
28. White D, Wallwork J: Xenografting: Probability, possibility, or pipe dream? Lancet 1993, 342:879
29. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160:1558
30. Akami T, Sawada R, Minato N, et al: Cytoprotective effect of CD59 antigen on xenotransplantation immunity. Transplant Proc 1992, 24:485
31. White DJG, Oglesby T, Liszewski MK, et al: Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc 1992, 24:474
32. Atkinson JP, Oglesby TJ, White D, et al: Separation of self from non-self in the complement system: A role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991, 86:27 (supp 1)
33. Oglesby TJ, Allen CJ, Liszewski MK, et al: Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism.J Exp Med 1992, 175:1547
34. Cary N, Moody J, Yannoutsos N, et al: Tissue expression of human decay accelerating factor, a regulator of complemenent activation expressed in mice: A potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993, 25:400
35. Logan JS, Martin MJ: Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol 1994, 231:435
36. Kooyman D, Byrne GW, McClellan S, et al: Erythroid-specific expression of human CD59 and transfer to vascular endothelial cells. Transplant Proc 1994, 26:1241
37. Kooyman DL, Byrne GW, McClellan S, et al: In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995, 269:89
38. Kagan DT, Platt JL, Logan JS, et al: Expression of complement regulatory factors using heterologous promoters in transgenic mice. Transplant Proc 1991, 26:1242
39. McCurry KR, Kooyman DL, Diamond L, et al: Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995, 59:1177
40. Diamond LE, McCurry KR, Platt JL, et al: A human CD59 minigene encodes a biologically functional complement regulatory protein in transgenic mice. Transpl Immunol 1995, 3:305
41. Diamond LE, Oldham ER, Platt JL, et al: Cell and tissue specific expression of a human CD59 minigene in transgenic mice. Transplant Proc 1994, 26:1239
42. Diamond LE, McCurry KR, Oldham ER, et al: Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996, (in press)
43. Byrne GW, McCurry KR, Kagan D, et al: Protection of xenogenic endothelium from human complement by expression of CD59 or DAF in transgenic mice. Transplantation 1995, 60:1149
44. Rosengard AM, Cary NRB, Langford GA, et al: Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 1995, 59:1325
45. Fodor WL, Williams BL, Matis LA, et al: Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994, 91:11153
46. McCurry KR, Kooyman DL, Alvarado CG, et al: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Medicine 1995, 1:423
47. Saadi S, Platt JL: Transient perturbation of endothelial integrity induced by antibodies and complement. J Exp Med 1995, 181:21
48. Good AH, Cooper DKC, Malcolm AJ, et al: Identification of carbohydrate structures that bind human antiporcine antibodies: Implications for discordant xenografting in humans. Transplant Proc 1992, 24:559
49. Sandrin MS, Vaughan HA, Dabkowski PL, et al: Anti-pig IgM antibodies in human serum react predominantly with Gala(1,3)Gal epitopes. Proc Natl Acad Sci USA 1993, 90:11391
50. Galili U, Swanson K: Gene sequences suggest inactivation of a-1, 3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 1991, 88:7401
51. Cooper DKC, Good AH, Koren E, et al: Identification of a-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transpl Immunol 1993, 1:198
52. Sandrin MS, Fodor WL, Mouhtouris E, et al: Enzymatic remodelling of the carbohydrate surface of xenogeneic cell substantially reduces human antibody binding and complement mediated cytolysis. Nature Medicine 1995, 1:1261